Mobile

A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (ant...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-008359-40

A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of AIN457 at 6 weeks on mean CDAI

Critère d'inclusion

  • Moderate to severe Crohn's disease (CDAI = 220 and =450)

Liens